NeoGenomics (NEO) Tops Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. COIN
4. PINS
5. RDDT
6. FSLR
7. SYK
8. DASH
9. SBUX
10. SNDK

Go back to NeoGenomics (NEO) Tops Q2 EPS by 1c

NeoGenomics Reports Record Revenue of $67.7 Million with 14% Increase in Clinical Volume Growth and 95% Increase in Pharma Services Backlog

July 24, 2018 7:00 AM EDT

The Company adopted ASC 606, effective January 1, 2018, using the full retrospective method of adoption.  Unless otherwise indicated, all financial results have been restated as if the Company had adopted this standard on January 1, 2017.

FT. MYERS, Fla., July 24, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2018.

Second Quarter 2018 Highlights:

 9% increase in consolidated revenue; 12% excluding PathLogic  14% increase in clinical genetic testing volume(1)  22% increase in Pharma Services... More